menu
    • menu
    [{"orgOrder":0,"company":"Engage Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Engage Therapeutics reports positive results from Phase 2 study of Staccato alprazolam for epileptic seizures\n","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Alprazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Engage Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Engage Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Engage The.."},{"orgOrder":0,"company":"Engage Therapeutics","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"$270\u202c.0 million","upfrontCash":"$125.0 million","newsHeadline":"UCB Acquires Engage Therapeutics for Staccato\u00ae Alprazolam","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Acquisition","leadProduct":"Alprazolam","moa":"GABA A receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Engage Therapeutics","amount2":0.27000000000000002,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0.27000000000000002,"dosageForm":"Inhalation","sponsorNew":"Engage Therapeutics \/ UCB","highestDevelopmentStatusID":"10","companyTruncated":"Engage The.."},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diamyd Medical Reports that Clinical Trial with Remygen[\u00ae] is Expanded to Evaluate Prevention of Hypoglycaemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Gamma-Aminobutyric Acid","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Diamyd Medical AB","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Diamyd Med.."}]

    Find Clinical Drug Pipeline Developments & Deals for Alplax

    Menu

    Alplax

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Diamyd Medical AB

                            Sweden arrow
                            Formnext Forum
                            Not Confirmed

                            Diamyd Medical AB

                            Sweden arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gamma-Aminobutyric Acid,Alprazolam

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Diamyd Medical Reports that Clinical Trial with Remygen[®] is Expanded to Evaluate Prevention of Hypoglycaemi...

                            Details : The Swedish Medical Products Agency has approved an amendment to ReGenerate-1 to investigate Remygen®'s preventive effects on hypoglycaemia (severely reduced blood sugar level) in individuals with long-term type 1 diabetes.

                            Brand Name : Remygen

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 24, 2020

                            Lead Product(s) : Gamma-Aminobutyric Acid,Alprazolam

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Engage Therapeutics

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Engage Therapeutics

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alprazolam

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : UCB Pharma S.A

                            Deal Size : $270‬.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            UCB Acquires Engage Therapeutics for Staccato® Alprazolam

                            Details : With is acquisition, UCB will have world-wide rights to Staccato[®] Alprazolam and would perform further clinical development, submission, launch and commercialization of Staccato[®] Alprazolam.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $125.0 million

                            June 05, 2020

                            Lead Product(s) : Alprazolam

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : UCB Pharma S.A

                            Deal Size : $270‬.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Engage Therapeutics

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Engage Therapeutics

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alprazolam

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Engage Therapeutics reports positive results from Phase 2 study of Staccato alprazolam for epileptic seizures

                            Details : Staccato alprazolam has demonstrated the ability to rapidly terminate seizures in patients with epilepsy in two minutes or less and prevent recurrence of seizure within two hours.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 12, 2020

                            Lead Product(s) : Alprazolam

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            Close
                            4